Expression levels and patterns of B‐cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent

Background Many novel therapies are being evaluated for the treatment of Multiple myeloma (MM). The cell‐surface protein B‐cell maturation antigen (BCMA, CD269) has recently emerged as a promising target for CAR‐T cell and monoclonal‐antibody therapies in MM. However, the knowledge of the BCMA expre...

Full description

Saved in:
Bibliographic Details
Published in:Cytometry. Part B, Clinical cytometry Clinical cytometry, 2022-11, Vol.102 (6), p.462-470
Main Authors: Sriram, Harshini, Kunjachan, Florence, Khanka, Twinkle, Gawai, Sangamitra, Ghogale, Sitaram, Deshpande, Nilesh, Girase, Karishma, Patil, Jagruti, Chatterjee, Gaurav, Rajpal, Sweta, Patkar, Nikhil V., Bagal, Bhausaheb, Jain, Hasmukh, Sengar, Manju, Hasan, Syed Khizer, Khattry, Navin, Subramanian, Papagudi G., Gujral, Sumeet, Tembhare, Prashant R.
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies
Antigen-presenting cells
Antigens
B-Cell Maturation Antigen - metabolism
Bone marrow
CD269
Cell surface
Coefficient of variation
Diagnosis
Female
Flow Cytometry
Fluorescence
Humans
Immunofluorescence
Immunotherapy
Immunotherapy, Adoptive
Lymphocytes
Lymphocytes T
Male
Maturation
Middle Aged
Multiple myeloma
Multiple Myeloma - metabolism
Neoplasm Recurrence, Local
Patients
Plasma cells
Protein B
targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Many novel therapies are being evaluated for the treatment of Multiple myeloma (MM). The cell‐surface protein B‐cell maturation antigen (BCMA, CD269) has recently emerged as a promising target for CAR‐T cell and monoclonal‐antibody therapies in MM. However, the knowledge of the BCMA expression‐pattern in myeloma patients from the Indian subcontinent is still not available. We present an in‐depth study of BCMA expression‐pattern on abnormal plasma cells (aPC) in Indian MM patients. Methods We studied BM samples from 217 MM patients (211‐new and 6‐relapsed) with a median age of 56 years (range, 30–78 years & M:F‐2.29) and 20 control samples. Expression levels/patterns of CD269 (clone‐19f2) were evaluated in aPCs from MM patients and in normal PCs (nPC) from uninvolved staging bone marrow samples (controls) using multicolor flow cytometry (MFC). Expression‐level of CD269 was determined as a ratio of mean fluorescent intensity (MFI‐R) of CD269 in PCs to that of non‐B‐lymphocytes and expression‐pattern (homogenous/heterogeneous) as coefficient‐of‐variation of immunofluorescence (CVIF). Results Median (range) percentage of CD269‐positive abnormal‐PCs in total PCs was 71.6% (0.49–99.29%). The MFI‐R (median, range) of CD269 was significantly higher in aPCs (4.13, 1.12–26.88) than nPCs (3.33, 1.23–12.87), p 
ISSN:1552-4949
1552-4957
DOI:10.1002/cyto.b.22099